Why Cooper Stock Plunges After Earnings - Cooper Companies (NASDAQ:COO)
Cooper Companies (COO) shares fell 14% after reporting Q3 revenue of $1.066B, missing estimates. EPS beat at $1.15. Guidance for Q4 was lower than expected. Analysts cut price targets, with a new consensus of $79. COO trades 23.4% below its 20-day SMA.
How this was made
The 30-second read
Why it matters
The market is repricing the stock on guidance and the expected persistence of inventory pressure into Q4, despite a non-GAAP EPS beat and a larger buyback authorization.
Market read
Traders should treat this as a guidance reset tied to inventory normalization risk, with technical oversold conditions potentially creating short-covering rallies.
What to watch
Analyst target cuts may be more about near-term conservatism than long-term fundamentals; the increased $3B buyback authorization could partially offset valuation pressure if investors believe the inventory overhang is temporary.
Background
Cooper completed a strategic review and decided to retain CooperSurgical, while investors focused on CooperVision inventory reduction effects and weaker near-term guidance.
Ticker impact
Cooper guided fiscal Q4 EPS to $1.05-$1.09 and revenue to $1.057B-$1.080B, below consensus, after inventory pressure at CooperVision.
Near term, downside risk remains elevated until investors gain confidence inventory normalization is progressing; oversold conditions may support a technical rebound but likely not a full trend reversal without better Q4 read-through.
The article cites specific guidance shortfalls versus analyst estimates and management commentary that inventory pressure will continue into Q4, which typically sustains multiple compression even if EPS beat on a non-GAAP basis.
Market effects
Signals continued demand and channel-inventory digestion risk in healthcare medtech/vision exposure, potentially pressuring near-term sentiment for similar inventory-heavy models.
Primarily US-listed healthcare sentiment; no explicit regional spillover beyond S&P 500 and Health Care sector weakness cited.
Limited direct global read-through in the article; impact is mostly company-specific guidance and inventory dynamics.
Counterpoint
The quarter’s non-GAAP EPS beat and management’s note that U.S. consumption rose mid-single digits suggest underlying demand may be healthier than reported sales, supporting a rebound if inventory clears faster than feared.
Key entities
- public_companyCooper Companies, Inc.
Subject of the article; fiscal Q3 results and Q4 guidance drove the selloff.
- business_unitCooperVision
U.S. channel inventory reduction weighed on results and is expected to continue into Q4.
- business_unitCooperSurgical
Retained after the strategic review; not sold in the review outcome.
